In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Medical Services Patients & Visitors Health Library For Medical Professionals Quality About Us PhysicianLink
Text Size:  -   +  |  Print Page  |  Email Page

Pulmonary Research



Research is one of the components that make us unique at Baptist Health Lexington.  Our highly trained staff is dedicated to providing the latest innovations and newest therapies in a community-based setting.  Baptist Health Lexington is working to improve the lives of our patients with pulmonary disease.

Below is a listing of current pulmonary clinical trials:

ASCEND Trial:
For patients diagnosed with idiopathic pulmonary fibrosis (IPF).

Purpose:  To test the benefits and safety of an investigational drug, pirfenidone, as compared to placebo.  

Eligibility:  Patients must be 40-80, not smoking, and diagnosed with IPF for at least 6 months. 

For more information please call Jeannie H. Chapman at 859-260-6172 or Jeannie.chapman@bhsi.com.

IRB 1036: Asthma Study:

Study Title: A 26 week, randomized, double-blind, parallel, group, active controlled multicenter, multinational safety study evaluating the risk of serious asthma-related events during the treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting b2-agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (>12 years of age) patients with asthma Study code: D5896C00027

Purpose: This study, which was mandated by the United States Food and Drug Administration (FDA), is being done to help answer an important safety question about long acting beta-agonists, a type of drug to treat asthma, specifically formoterol, a component of Symbicort.

Primary eligibility: Have had a clinical diagnosis of asthma for at least 1 year; with at least 1 asthma exacerbation treated with systemic corticosteroids in last 12 months and be treating their asthma daily.

For additional information, please contact Jeannie Chapman at 859.260.6172, Ruthie Hoefner at 859.260.4527 or Karen Willis at 859.260.6440

 IRB 1043: COPD Study:

Study Title:  A randomized, placebo-controlled, double-blind, parallel group, multi-center study to assess the safety and efficacy of tiotropium bromide (18 μg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD) subjects recovering from hospitalization for an acute exacerbation (Hospital Discharge Study 2). Protocol Number: 205.478

Purpose:

  • Test the safety and effectiveness of the study drug, tiotropium bromide
  • Test the effect of starting treatment with tiotropium bromide in patients recovering from an acute COPD exacerbation which required hospitalization

Tiotropium bromide, the study drug, is an inhaled bronchodilator (medications used to treat COPD and other lung disorders which relax the airways of the lungs making it easier to breathe) that is approved by the United States Food and Drug Administration (FDA) to treat COPD. Tiotropium bromide is marketed under the brand name Spiriva®.

 Primary eligibility: Male or female subjects 40 years of age or older with a recent hospitalization (<10 days prior to study enrollment) for acute COPD exacerbation.

 For additional information, please contact Jeannie Chapman at 859.260.6172, Ruthie Hoefner at 859.260.4527 or Karen Willis at 859.260.6440

 IRB 1037: IPF Extended Study:

Study Title: An open-label extension trial of the long term safely of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF): Protocol number 1199.33

 Purpose:

  • Provide BIBF 1120 study drug treatment for all subjects who have completed the 52 week treatment period and the follow-up period in the parent trial (study 1199.34)
  • Determine the tolerability and safety in BIBF 1120 when given for a long term period to subjects with Idiopathic Pulmonary Fibrosis (IPF)

Primary eligibility: Patients with IPF who have participated and completed the 52 week treatment period and the follow-up period in the parent trial (study 1199.34)

For additional information, please contact Jeannie Chapman at 859.260.6172.